title: Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene.
authors.forename: J J W M
authors.initials: JJ
authors.lastname: Janssen
authors.forename: A
authors.initials: A
authors.lastname: Hochhaus
authors.forename: J W
authors.initials: JW
authors.lastname: van Oostveen
authors.forename: Q
authors.initials: Q
authors.lastname: Waisfisz
authors.forename: G J
authors.initials: GJ
authors.lastname: Schuurhuis
authors.forename: G J
authors.initials: GJ
authors.lastname: Ossenkoppele
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D016044:Fusion Proteins, bcr-abl / Q000737:chemistry / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D011743:Pyrimidines / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000032:analysis
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D012333:RNA, Messenger; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl